Online inquiry

IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13111MR)

This product GTTS-WQ13111MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ACVRL1 gene. The antibody can be applied in Hepatocellular carcinoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000020.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 94
UniProt ID P37023
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13111MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6937MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ENIA11
GTTS-WQ8485MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA hu1124
GTTS-WQ11468MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ10378MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY2062430
GTTS-WQ6861MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DX-2930
GTTS-WQ14549MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SAR156597
GTTS-WQ9208MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-106
GTTS-WQ8686MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuMax-TF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW